Literature DB >> 3825999

Histologic classification and staging of multiple myeloma. A retrospective and prospective study of 674 cases.

R Bartl, B Frisch, A Fateh-Moghadam, G Kettner, K Jaeger, W Sommerfeld.   

Abstract

Bone marrow biopsies of 674 patients with multiple myeloma (MM) were processed for diagnostic evaluation. Histologic variables were correlated with the clinical features to determine factors of value in predicting prognosis. Four of these were used to classify MM into six histologic types: Marschalko type; small cell type; cleaved type; polymorphous type; asynchronous type; and blastic type. These six types were subsequently combined into three prognostic grades: low, intermediate, and high, analogous to the malignant lymphomas. The quantity of plasma cell burden in the biopsy proved to be a useful criterion for histologic staging of MM, supplementing any clinical staging system in use. Both these parameters, grade and stage, provide information required for decisions on treatment modalities, while the effects of therapy can be monitored by sequential biopsies.

Entities:  

Mesh:

Year:  1987        PMID: 3825999     DOI: 10.1093/ajcp/87.3.342

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  40 in total

1.  Evaluation of argyrophilic nucleolar organiser regions (AgNORs) in multiple myeloma.

Authors:  S I Papadhimitriou; D Daskalopoulou; P Tsaftaridis; S Markidou; M Stamatelou
Journal:  J Clin Pathol       Date:  2000-06       Impact factor: 3.411

2.  Multiparameter analyses of normal and malignant human plasma cells: CD38++, CD56+, CD54+, cIg+ is the common phenotype of myeloma cells.

Authors:  R Leo; M Boeker; D Peest; R Hein; R Bartl; J E Gessner; J Selbach; G Wacker; H Deicher
Journal:  Ann Hematol       Date:  1992-03       Impact factor: 3.673

3.  Bone marrow trephine biopsy in lymphoproliferative disease.

Authors:  C Schmid; P G Isaacson
Journal:  J Clin Pathol       Date:  1992-09       Impact factor: 3.411

4.  Argyrophilic nucleolar organizer region counts in multiple myeloma: a histopathological study on bone marrow trephine biopsies.

Authors:  A Pich; L Chiusa; F Marmont; N Cappello; R Navone
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1992

5.  Anaplastic plasmacytoma of mouse--establishing parallels between subtypes of mouse and human plasma cell neoplasia.

Authors:  Daphne de Jong; Siegfried Janz
Journal:  J Pathol       Date:  2010-07       Impact factor: 7.996

6.  Nodal and extranodal plasmacytomas expressing immunoglobulin a: an indolent lymphoproliferative disorder with a low risk of clinical progression.

Authors:  Haipeng Shao; Liqiang Xi; Mark Raffeld; Stefania Pittaluga; Kieron Dunleavy; Wyndham H Wilson; Nelson Spector; Cristiane Milito; Jose Carlos Morais; Elaine S Jaffe
Journal:  Am J Surg Pathol       Date:  2010-10       Impact factor: 6.394

7.  Assessment of bone marrow plasma cell infiltrates in multiple myeloma: the added value of CD138 immunohistochemistry.

Authors:  Samer Z Al-Quran; Lijun Yang; James M Magill; Raul C Braylan; Vonda K Douglas-Nikitin
Journal:  Hum Pathol       Date:  2007-08-21       Impact factor: 3.466

8.  Multiple myeloma presenting as extramedullary plasmacytoma of the thyroid, advanced grade II-III plasmablastic type.

Authors:  V L Schiller; A L Deutsch; R R Turner
Journal:  Skeletal Radiol       Date:  1995-05       Impact factor: 2.199

9.  Chromogenic in situ hybridization for the detection of lambda and kappa immunoglobulin light chains as a potential auxiliary diagnostic technique in canine plasmacytomas.

Authors:  Greta Foiani; Claudia Zanardello; Antonio Carminato; Erica Melchiotti; Paola Roccabianca; Marco Tecilla; Marta Vascellari
Journal:  J Vet Diagn Invest       Date:  2020-07-05       Impact factor: 1.279

10.  Combined evaluation of bone marrow aspirate and biopsy is superior in the prognosis of multiple myeloma.

Authors:  Sanja Stifter; Emina Babarović; Toni Valković; Irena Seili-Bekafigo; Christophe Stemberger; Antica Nacinović; Ksenija Lucin; Nives Jonjić
Journal:  Diagn Pathol       Date:  2010-05-18       Impact factor: 2.644

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.